Skip to main content
 
June 19, 2018
Patent granted for groundbreaking work by Jennifer Doudna’s and Emmanuelle Charpentier’s research teams in CRISPR/Cas9 genome editing technology Patent covers use of optimized guide RNA molecules
May 3, 2018

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer. In this role, Tim will lead the company's efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities.

July 25, 2017
Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence of multiple groups readily applying CRISPR/Cas9 gene editing to eukaryotic cells following teachings of Charpentier-Doudna team
July 6, 2017

BERKELEY, CA– July 6, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.

May 10, 2017
Patent covers foundational CRISPR-Cas9 inventions for which Caribou holds an exclusive license from the University of California and the University of Vienna Claims cover CRISPR-Cas9 compositions for use in any non-cellular and cellular setting, including eukaryotic cells

Pages